BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 37294698)

  • 1. Diabetes and Prostate Cancer Outcomes in Men with Nonmetastatic Castration-Resistant Prostate Cancer: Results from the SEARCH Cohort.
    Sergeyev A; Gu L; De Hoedt AM; Amling CL; Aronson WJ; Cooperberg MR; Kane CJ; Klaassen Z; Terris MK; Guerrios-Rivera L; Freedland SJ; Csizmadi I
    Cancer Epidemiol Biomarkers Prev; 2023 Sep; 32(9):1208-1216. PubMed ID: 37294698
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Poorly controlled diabetes increases the risk of metastases and castration-resistant prostate cancer in men undergoing radical prostatectomy: Results from the SEARCH database.
    Nik-Ahd F; Howard LE; Eisenberg AT; Aronson WJ; Terris MK; Cooperberg MR; Amling CL; Kane CJ; Freedland SJ
    Cancer; 2019 Aug; 125(16):2861-2867. PubMed ID: 31034601
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Diabetes and Prostate Cancer Outcomes in Obese and Nonobese Men After Radical Prostatectomy.
    Kelkar S; Oyekunle T; Eisenberg A; Howard L; Aronson WJ; Kane CJ; Amling CL; Cooperberg MR; Klaassen Z; Terris MK; Freedland SJ; Csizmadi I
    JNCI Cancer Spectr; 2021 Jun; 5(3):. PubMed ID: 34169227
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Thresholds for PSA doubling time in men with non-metastatic castration-resistant prostate cancer.
    Howard LE; Moreira DM; De Hoedt A; Aronson WJ; Kane CJ; Amling CL; Cooperberg MR; Terris MK; Freedland SJ
    BJU Int; 2017 Nov; 120(5B):E80-E86. PubMed ID: 28371163
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Obese patients with castration-resistant prostate cancer may be at a lower risk of all-cause mortality: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database.
    Vidal AC; Howard LE; de Hoedt A; Kane CJ; Terris MK; Aronson WJ; Cooperberg MR; Amling CL; Freedland SJ
    BJU Int; 2018 Jul; 122(1):76-82. PubMed ID: 29521009
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of age, comorbidity, and PSA doubling time on long-term competing risks for mortality among men with non-metastatic castration-resistant prostate cancer.
    Whitney CA; Howard LE; Freedland SJ; DeHoedt AM; Amling CL; Aronson WJ; Cooperberg MR; Kane CJ; Terris MK; Daskivich TJ
    Prostate Cancer Prostatic Dis; 2019 May; 22(2):252-260. PubMed ID: 30279582
    [TBL] [Abstract][Full Text] [Related]  

  • 7. First-year weight loss with androgen-deprivation therapy increases risks of prostate cancer progression and prostate cancer-specific mortality: results from SEARCH.
    Griffin K; Csizmadi I; Howard LE; Pomann GM; Aronson WJ; Kane CJ; Amling CL; Cooperberg MR; Terris MK; Beebe-Dimmer J; Freedland SJ
    Cancer Causes Control; 2019 Mar; 30(3):259-269. PubMed ID: 30701374
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prostate-specific Antigen Progression in Enzalutamide-treated Men with Nonmetastatic Castration-resistant Prostate Cancer: Any Rise in Prostate-specific Antigen May Require Closer Monitoring.
    Saad F; Sternberg CN; Efstathiou E; Fizazi K; Modelska K; Lin X; Sugg J; Steinberg J; Noerby B; Shore ND; Hussain M
    Eur Urol; 2020 Dec; 78(6):847-853. PubMed ID: 33010985
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of treatment on progression to castration-resistance, metastases, and death in men with localized high-grade prostate cancer.
    Miller ET; Chamie K; Kwan L; Lewis MS; Knudsen BS; Garraway IP
    Cancer Med; 2017 Jan; 6(1):163-172. PubMed ID: 27997745
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prostate weight and prostate cancer outcomes after radical prostatectomy: Results from the SEARCH cohort study.
    Barlow SK; Oyekunle T; Janes JL; De Hoedt AM; Aronson WJ; Kane CJ; Amling CL; Cooperberg MR; Klaassen ZW; Terris MK; Freedland SJ; Csizmadi I
    Prostate; 2022 Feb; 82(3):366-372. PubMed ID: 34905632
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Obesity, race, and long-term prostate cancer outcomes.
    Vidal AC; Oyekunle T; Howard LE; De Hoedt AM; Kane CJ; Terris MK; Cooperberg MR; Amling CL; Klaassen Z; Freedland SJ; Aronson WJ
    Cancer; 2020 Aug; 126(16):3733-3741. PubMed ID: 32497282
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Race does not predict skeletal-related events and all-cause mortality in men with castration-resistant prostate cancer.
    Patel DN; Howard LE; De Hoedt AM; Amling CL; Aronson WJ; Cooperberg MR; Kane CJ; Klaassen ZW; Terris MK; Freedland SJ
    Cancer; 2020 Jul; 126(14):3274-3280. PubMed ID: 32374476
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Race does not predict the development of metastases in men with nonmetastatic castration-resistant prostate cancer.
    Whitney CA; Howard LE; Amling CL; Aronson WJ; Cooperberg MR; Kane CJ; Terris MK; Freedland SJ
    Cancer; 2016 Dec; 122(24):3848-3855. PubMed ID: 27505036
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lycopene, tomato products and prostate cancer-specific mortality among men diagnosed with nonmetastatic prostate cancer in the Cancer Prevention Study II Nutrition Cohort.
    Wang Y; Jacobs EJ; Newton CC; McCullough ML
    Int J Cancer; 2016 Jun; 138(12):2846-55. PubMed ID: 26830232
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Positive surgical margins in radical prostatectomy patients do not predict long-term oncological outcomes: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) cohort.
    Mithal P; Howard LE; Aronson WJ; Terris MK; Cooperberg MR; Kane CJ; Amling C; Freedland SJ
    BJU Int; 2016 Feb; 117(2):244-8. PubMed ID: 26010160
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Survival and Economic Impact of Rapid Prostate-Specific Antigen Doubling Time in Patients With Nonmetastatic Castration-Resistant Prostate Cancer.
    Freedland SJ; Ramaswamy K; Huang A; Sandin R; Mardekian J; Schultz NM; Janjan N; George DJ
    Clin Genitourin Cancer; 2023 Aug; 21(4):419-429. PubMed ID: 36842915
    [TBL] [Abstract][Full Text] [Related]  

  • 17. How PET-CT is Changing the Management of Non-metastatic Castration-resistant Prostate Cancer?: Comment la TEP-TDM Peut Modifier la Prise en Charge du Cancer de la Prostate Non Métastatique Résistant à la Castration ?
    Baboudjian M; Gauthé M; Barret E; Brureau L; Rocchi P; Créhange G; Dariane C; Fiard G; Fromont G; Beauval JB; Mathieu R; Renard-Penna R; Roubaud G; Ruffion A; Sargos P; Rouprêt M; Ploussard G
    Prog Urol; 2022 Jun; 32(6S1):6S43-6S53. PubMed ID: 36719646
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In Men with Castration-Resistant Prostate Cancer, Visceral Metastases Predict Shorter Overall Survival: What Predicts Visceral Metastases? Results from the SEARCH Database.
    Whitney CA; Howard LE; Posadas EM; Amling CL; Aronson WJ; Cooperberg MR; Kane CJ; Terris MK; Freedland SJ
    Eur Urol Focus; 2017 Oct; 3(4-5):480-486. PubMed ID: 28753787
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predictors of skeletal-related events and mortality in men with metastatic, castration-resistant prostate cancer: Results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database.
    Tablazon IL; Howard LE; De Hoedt AM; Aronson WJ; Kane CJ; Amling CL; Cooperberg MR; Terris MK; Freedland SJ; Williams SB
    Cancer; 2019 Nov; 125(22):4003-4010. PubMed ID: 31390061
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Improving Clinical Risk Stratification at Diagnosis in Primary Prostate Cancer: A Prognostic Modelling Study.
    Gnanapragasam VJ; Lophatananon A; Wright KA; Muir KR; Gavin A; Greenberg DC
    PLoS Med; 2016 Aug; 13(8):e1002063. PubMed ID: 27483464
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.